CONNECT BIOPHARMA HOLDINGS LIMITED Financials Connect Biopharma Holdings Limited
Equities
CNTB
US2075231017
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | -1.47% |
|
-12.99% | +13.56% |
| Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
| Apr. 17 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,735 | 329.3 | 461.2 | 535 | - | - |
| Enterprise Value (EV) 2 | 28.46 | -729.2 | 461.2 | -295.1 | -952.1 | -424.9 |
| P/E ratio | -1.31 x | -0.41 x | -1.09 x | -2.49 x | -1.77 x | -1.37 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 0.47 x | 2.09 x | 2.59 x |
| EV / Revenue | - | - | - | -0.26 x | -3.72 x | -2.06 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -0.05 x | 1.07 x | - | -0.47 x | 2.99 x | 1.03 x |
| FCF Yield | -2,005% | 93.2% | - | -213% | 33.5% | 97.1% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 53,023 | 55,016 | 55,072 | 55,101 | - | - |
| Reference price 3 | 5.150 | 0.8678 | 1.180 | 1.340 | 1.340 | 1.340 |
| Announcement Date | 3/31/22 | 4/11/23 | 4/16/24 | - | - | - |
1USD in Million2CNY in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 1,142 | 255.8 | 206.7 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -631.4 | -772.8 | -449.3 | 607.3 | -334.4 | -474.1 |
| Operating Margin | - | - | - | - | 53.16% | -130.71% | -229.4% |
| Earnings before Tax (EBT) | - | -1,305 | -795 | - | - | - | - |
| Net income 1 | -779.2 | -1,307 | -797.1 | -430.7 | -215.4 | -437.9 | -567.5 |
| Net margin | - | - | - | - | -18.86% | -171.16% | -274.59% |
| EPS 2 | -4.048 | -3.943 | -2.105 | -1.080 | -0.5390 | -0.7580 | -0.9760 |
| Free Cash Flow 1 | - | -570.8 | -679.7 | - | 629.7 | -318.5 | -412.6 |
| FCF margin | - | - | - | - | 55.13% | -124.48% | -199.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/26/21 | 3/31/22 | 4/11/23 | 4/16/24 | - | - | - |
1CNY in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | 152 | 990.3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -181.4 | -181.4 | -363.1 | -205.5 | -205.5 | -401.8 | - | - | - | -101.3 | 708.6 |
| Operating Margin | - | - | - | - | - | - | - | - | - | -66.67% | 71.56% |
| Earnings before Tax (EBT) 1 | -181.3 | -181.3 | - | -200.3 | -200.3 | -400.5 | - | - | - | - | - |
| Net income 1 | -182.2 | -182.2 | -364.3 | -200.6 | -200.6 | -401.3 | -395.8 | -212 | - | -135.2 | -80.2 |
| Net margin | - | - | - | - | - | - | - | - | - | -88.94% | -8.1% |
| EPS 2 | -0.5000 | -0.5000 | -0.7729 | -0.5256 | -0.5256 | -1.054 | -1.045 | -0.5348 | - | -0.3410 | -0.2020 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 3/31/22 | 3/31/22 | 9/13/22 | 9/13/22 | 9/13/22 | 4/11/23 | 9/12/23 | 4/16/24 | - | - |
1CNY in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,706 | 1,059 | - | 830 | 1,487 | 960 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -571 | -680 | - | 630 | -318 | -413 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 24.9 | - | - | 7.24 | 7.24 | 14.5 |
| Capex / Sales | - | - | - | - | 0.63% | 2.83% | 7% |
| Announcement Date | 2/26/21 | 3/31/22 | 4/11/23 | 4/16/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.34
USD
Average target price
7
USD
Spread / Average Target
+422.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.56% | 73.84M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CNTB Stock
- Financials Connect Biopharma Holdings Limited
